LLY logo

LLY
Lilly(Eli) & Co

31,864
Mkt Cap
$931.18B
Volume
2.28M
52W High
$1,133.95
52W Low
$623.78
PE Ratio
43.61
LLY Fundamentals
Price
$989.12
Prev Close
$985.08
Open
$991.98
50D MA
$1,038.87
Beta
0.68
Avg. Volume
3.82M
EPS (Annual)
$22.95
P/B
35.07
Rev/Employee
$1.3M
$1,003,056.77
Loading...
Loading...
News
all
press releases
Promising Pharmaceutical Stocks To Keep An Eye On - March 16th
Eli Lilly and Company, CytomX Therapeutics, Pfizer, HCW Biologics, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Best Medical Stocks To Watch Today - March 16th
Eli Lilly and Company, CytomX Therapeutics, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...
MarketBeat·3h ago
News Placeholder
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price?
Key PointsEli Lilly's growth rate has accelerated significantly in recent years due to its GLP-1 drugs...
Nasdaq News: Markets·5h ago
News Placeholder
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·8h ago
News Placeholder
Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial
Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.read more...
Benzinga·8h ago
News Placeholder
Hilltop Holdings Inc. Acquires 8,154 Shares of Eli Lilly and Company $LLY
Hilltop Holdings Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 97.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The...
MarketBeat·10h ago
News Placeholder
Holocene Advisors LP Has $114.14 Million Stock Position in Eli Lilly and Company $LLY
Holocene Advisors LP decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 78.0% during the 3rd quarter, according to the company in its most recent 13F filing with...
MarketBeat·10h ago
News Placeholder
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic...
PR Newswire·10h ago
News Placeholder
ICONIQ Capital LLC Cuts Position in Eli Lilly and Company $LLY
ICONIQ Capital LLC decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 90.4% during the third quarter, according to the company in its most recent filing with the Securities...
MarketBeat·10h ago
News Placeholder
Fred Alger Management LLC Has $73.09 Million Stock Holdings in Eli Lilly and Company $LLY
Fred Alger Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 39.2% during the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·11h ago
<
1
2
...
>

Latest LLY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.